Acetaminophen (Paracetamol)

Twycross, Robert; Pace, Victor; Mihalyo, Mary; Wilcock, Andrew

doi:10.1016/j.jpainsymman.2013.08.001

Cited by 39 publications

(28 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three polymorphs of this compound have been obtained at ambient pressure, and all have different physical properties that are related to the differences in crystal structures. [13][14][15][16] There is evidence that an isomeric compound, metacetamol ĲN-acetyl-metaaminophenol) 17 (Scheme 1), is significantly less toxic, [18][19][20][21] although recent studies 23 make this statement questionable reporting that metacetamol may also be hepatotoxic like paracetamol. [9][10][11] Two additional polymorphs were recently reported to form reversibly at very high (above 8 GPa) pressures.…”

Section: Introductionmentioning

confidence: 99%

A new polymorph of metacetamol

et al. 2015

View full text Add to dashboard Cite

Metacetamol is a structural isomer of the widely used drug paracetamol and is being considered as a promising alternative to the latter because of its lower toxicity. Due to the importance of the well-known polymorphism of paracetamol, an investigation of the polymorphism of metacetamol was successfully undertaken. A new polymorph of metacetamol has been discovered and extensively characterised using a variety of analytical techniques (IR-and Raman spectroscopy, UV-visible optical spectroscopy, X-ray powder and single-crystal diffraction, TGA and DSC). A procedure for the reliable and reproducible preparation of the new polymorph is described. Its properties and crystal structure are compared with those of the previously known polymorph, as well as with those of paracetamol. CrystEngComm This journal isScheme 1 Molecular structures of metacetamol (left) and paracetamol (right) containing the same characteristic functional groups.

show abstract

Section: Introductionmentioning

confidence: 99%

A new polymorph of metacetamol

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In the paracetamol only group nausea (25%) and epigastric pain (16.7%) were noted and in agreement to the published reports 11,12 . In the ultracet group drowsiness was the main adverse effect noted (11.9%) other adverse effects being nausea (7.1%) constipation (7.1%), insomnia and headache as reported earlier [13][14][15] (Table 2). The tramadol group saw constipation as the main adverse effect (13.3%) with nausea and drowsiness being seen in 6.7% of the patients ( Table 2).…”

Section: Discussionmentioning

confidence: 76%

Audit of Efficacy and Adverse Events of Analgesics Used to Mitigating Cancer Pain: Observations From a Tertiary Care Hospital

Simon¹,

Palatty²,

Thilakchand³

et al. 2018

IJMLR

View full text Add to dashboard Cite

Introduction: Analgesics are the main stay in the mitigation of pain in cancer patients.However, depending on the type of analgesics, adverse events which at times can be severe are also observed. In this study an attempt has been made to understand the beneficial and adverse effects of the standard analgesics recommended for mitigating cancer pain. Materials and methods: This is a cross sectional prospective observational study with 150 cancer patients requiring analgesics and was conducted at the oncology ward of a tertiary care hospital. The prescription pattern, the mitigation of pain and the adverse events were recorded. Results: The results indicate that morphine injection was the most effective followed by morphine tablets, ultracet, tramadol and paracetamol. With regard to the adverse effects it was observed that 70.7% of the patients had one or other symptoms and that constipation (9.3%; 14/150) followed by nausea (8%; 12/150) and drowsiness (5.3%; 8/150) were the most common. Conclusion:The results of the study indicate that in spite of administering protective/ preventive drugs analgesic-induced adverse effects are common in cancer patients.

show abstract

“…6 It is most widely used for symptomatic control of fever associated with various bacterial/viral infections. Paracetamol is likely to be used as an antipyretic along with anti-tubercular drugs in the initial phase to counter the pyrexia before anti-tubercular drugs produce their effect.…”

Section: Introductionmentioning

confidence: 99%

“…NAPQI is an electrophile metabolite of the drug that binds covalently to the tissue macromolecules and probably also oxidizes nonprotein and protein thiols. 6 Hepatic microsomal enzyme cytochrome P-450 2E1 catalyses the formation of NAPQI and it is induced by isoniazid. 9 Due to increasing in oxidative metabolism of paracetamol, its hepatotoxicity may also increase.…”

Section: Introductionmentioning

confidence: 99%

“…10 However, some studies suggest that isoniazid can inhibit the microsomal oxidative metabolism of paracetamol. 6,9 In view of the above, so also conflicting reports on the effect of isoniazid on paracetamol metabolism, there is a possibility of an interaction of paracetamol with isoniazid that is also a hepatotoxic agent, thus may result in probable change in the pharmacokinetic profile as well as its efficacy and adverse effects. 8,11,12 The present study was, therefore, undertaken to explore the possible interaction of paracetamol with the commonly used primary anti-tubercular drug isoniazid in respect to its plasma concentration, efficacy and adverse effects in Albino rats.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation